http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 08:27:37 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Revolution+%28RVMD%29+PT+Raised+to+%24192.10+at+Wedbush/26805147.html Wedbush analyst Robert Driscoll raised the price target on Revolution (NASDAQ: RVMD) to $192.10 (from $181.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Revolution+%28RVMD%29+PT+Raised+to+%24192.10+at+Wedbush/26805147.html Thu, 23 Jul 2026 08:27:37 -0400 RVMD http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html <p>Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration accepted for review the company's New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma.</p> <p>The NDA is based on results from the global, randomized Phase 3 RASolute 302 trial, which compared daraxonrasib against standard-of-care cytotoxic chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma, with or without an identified tumor RAS mutation. The trial met all primary and key secondary endpoints, including improvements in overall survival and progression-free survival. Patients treated with daraxonrasib also reported delayed deterioration in cancer-related http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html Wed, 22 Jul 2026 16:05:48 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html <p>Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration accepted for review the company's New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma.</p> <p>The NDA is based on results from the global, randomized Phase 3 RASolute 302 trial, which compared daraxonrasib against standard-of-care cytotoxic chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma, with or without an identified tumor RAS mutation. The trial met all primary and key secondary endpoints, including improvements in overall survival and progression-free survival. Patients treated with daraxonrasib also reported delayed deterioration in cancer-related http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html Wed, 22 Jul 2026 16:05:48 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html <p>Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration accepted for review the company's New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma.</p> <p>The NDA is based on results from the global, randomized Phase 3 RASolute 302 trial, which compared daraxonrasib against standard-of-care cytotoxic chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma, with or without an identified tumor RAS mutation. The trial met all primary and key secondary endpoints, including improvements in overall survival and progression-free survival. Patients treated with daraxonrasib also reported delayed deterioration in cancer-related http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html Wed, 22 Jul 2026 16:05:48 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html <p>Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration accepted for review the company's New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma.</p> <p>The NDA is based on results from the global, randomized Phase 3 RASolute 302 trial, which compared daraxonrasib against standard-of-care cytotoxic chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma, with or without an identified tumor RAS mutation. The trial met all primary and key secondary endpoints, including improvements in overall survival and progression-free survival. Patients treated with daraxonrasib also reported delayed deterioration in cancer-related http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html Wed, 22 Jul 2026 16:05:48 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html <p>Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration accepted for review the company's New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma.</p> <p>The NDA is based on results from the global, randomized Phase 3 RASolute 302 trial, which compared daraxonrasib against standard-of-care cytotoxic chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma, with or without an identified tumor RAS mutation. The trial met all primary and key secondary endpoints, including improvements in overall survival and progression-free survival. Patients treated with daraxonrasib also reported delayed deterioration in cancer-related http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html Wed, 22 Jul 2026 16:05:48 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html <p>Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration accepted for review the company's New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma.</p> <p>The NDA is based on results from the global, randomized Phase 3 RASolute 302 trial, which compared daraxonrasib against standard-of-care cytotoxic chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma, with or without an identified tumor RAS mutation. The trial met all primary and key secondary endpoints, including improvements in overall survival and progression-free survival. Patients treated with daraxonrasib also reported delayed deterioration in cancer-related http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html Wed, 22 Jul 2026 16:05:48 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html <p>Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration accepted for review the company's New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma.</p> <p>The NDA is based on results from the global, randomized Phase 3 RASolute 302 trial, which compared daraxonrasib against standard-of-care cytotoxic chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma, with or without an identified tumor RAS mutation. The trial met all primary and key secondary endpoints, including improvements in overall survival and progression-free survival. Patients treated with daraxonrasib also reported delayed deterioration in cancer-related http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html Wed, 22 Jul 2026 16:05:48 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html <p>Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration accepted for review the company's New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma.</p> <p>The NDA is based on results from the global, randomized Phase 3 RASolute 302 trial, which compared daraxonrasib against standard-of-care cytotoxic chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma, with or without an identified tumor RAS mutation. The trial met all primary and key secondary endpoints, including improvements in overall survival and progression-free survival. Patients treated with daraxonrasib also reported delayed deterioration in cancer-related http://www.streetinsider.com/FDA/FDA+accepts+Revolution+Medicines+NDA+for+daraxonrasib+in+pancreatic+cancer/26801639.html Wed, 22 Jul 2026 16:05:48 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Press+Releases/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html <p align="justify">REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).</p> <p align="justify">“The FDA’s acceptance of the daraxonrasib NDA is an important step in the regulatory review process and brings us closer to the possibility of offering patients a new targeted medicine for previously treated metastatic http://www.streetinsider.com/Globe+Newswire/Revolution+Medicines%E2%80%99+New+Drug+Application+for+Daraxonrasib+Accepted+for+Review+by+U.S.+FDA+for+Previously+Treated+Metastatic+Pancreatic+Cancer/26801617.html Wed, 22 Jul 2026 16:05:00 -0400 A.06822034 A.09649487 A.50209015 O.00048429 O.00225875 O.20026344 O.26043287 RVMD